1	Evaluating the feasibility, sensitivity, and specificity of next-generation
2	molecular methods for pleural infection diagnosis
3	
4	Peter T. Bell ^{1,2,3 #} , Timothy Baird ^{1,2,4 #} , John Goddard ^{1,7} , Olusola S. Olagoke ^{2,4} , Andrew Burke ^{3,5} ,
5	Shradha Subedi ^{2,6} , Tiana R. Davey ^{2,4} , James Anderson ^{1,7} , Derek S. Sarovich ^{2,4,^} , and Erin P. Price ^{2,4,*}
6	#,^ Authors contributed equally
7	
8	¹ Department of Respiratory Medicine, Sunshine Coast University Hospital, Birtinya, Queensland,
9	Australia
10	² Sunshine Coast Health Institute, Birtinya, Queensland, Australia
11	³ School of Medicine, University of Queensland, Herston, Queensland, Australia
12	⁴ Centre for Bioinnovation, University of the Sunshine Coast, Sippy Downs, Queensland, Australia
13	⁵ Department of Respiratory and Thoracic Medicine, The Prince Charles Hospital, Chermside,
14	Queensland, Australia
15	⁶ Department of Infectious Diseases, Sunshine Coast University Hospital, Birtinya, Queensland,
16	Australia
17	⁷ School of Medicine and Dentistry, Griffith University, Sunshine Coast, Queensland, Australia
18	
19	*Corresponding Author
20	Erin P. Price
21	University of Sunshine Coast
22	eprice@usc.edu.au
23	+61 7 5456 5568
24	
25	Running Title: Molecular Methods for Pleural Infection Diagnosis
26	Total Manuscript Word Count: 3499
27	Abstract Word Count: 250
28	Keywords: empyema; metagenomics; high-throughput sequencing; parapneumonic effusion; pleural
29	infection; microbiome

30 Abstract

32	Rationale.	Pleural infections are commor	and associated with	substantial healthcare cost	. morbidity.
----	------------	-------------------------------	---------------------	-----------------------------	--------------

- 33 and mortality. Accurate pleural infection diagnosis remains challenging due to low culture positivity
- 34 rates, frequent polymicrobial involvement, and non-specific diagnostic biomarkers.
- 35 **Objective.** To undertake a prospective pilot study examining the feasibility and challenges associated
- 36 with molecular methods for diagnosing suspected pleural infection.
- 37 *Methods.* We prospectively characterised 26 consecutive, clinically suspected pleural infections, and
- 38 10 consecutive control patients with suspected non-infective pleural effusions, using shotgun
- 39 metagenomics, bacterial metataxonomics, quantitative PCR, and conventional culture.
- 40 **Results.** We demonstrate the feasibility of culture-independent molecular techniques for diagnosing
- 41 suspected pleural infection. Molecular methods exhibited excellent diagnostic performance, with each
- 42 method identifying 54% (14/26) positive cases among the pleural infection cohort, versus 38% (10/26)
- 43 with culture. Meta-omics methods unveiled complex polymicrobial infections largely missed by culture.
- 44 Dominant infecting microbes included streptococci (S. intermedius, S. pyogenes, S. mitis), Prevotella
- 45 spp. (P. oris, P. pleuritidis), staphylococci (S. aureus, S. saprophyticus), and Klebsiella pneumoniae.
- 46 However, we encountered challenges that complicated pleural infection interpretation, including: i)
- 47 uncertainties regarding microbial pathogenicity and the impact of prior antibiotic therapy on diagnostic
- 48 performance; ii) lack of a clinical diagnostic gold-standard for molecular performance comparisons; iii)
- 49 potential accidental microbial contamination during specimen collection and processing; and iv)
- 50 difficulties distinguishing background microbial noise from true microbial signal, particularly in low-
- 51 biomass specimens.
- 52 **Conclusions.** Our pilot study demonstrates the potential utility and value of molecular methods in 53 diagnosing pleural infection and highlights key concepts and challenges that should be addressed 54 when designing larger prospective trials.

55 Key messages

56

57 What is already known on this topic

- 58 Confident pleural infection diagnosis is often challenging due to low culture positivity rates, frequent
- 59 polymicrobial involvement, and non-specific diagnostic biomarkers. Limitations of conventional
- 60 diagnostic tests result in prolonged and inappropriately broad-spectrum antimicrobial use, leading to
- 61 potentially poorer patient outcomes and avoidable adverse effects.

62

63 What this study adds

- 64 We demonstrate the feasibility, utility, and challenges associated with the use of culture-independent
- 65 molecular techniques for more accurate pleural infection diagnosis in a real-world clinical setting.
- 66
- 67 How this study might affect research, practice, or policy
- 68 These data will help to inform the design of larger prospective clinical trials and identify potential
- 69 obstacles to be overcome as next-generation sequencing technologies become integrated into routine
- 70 clinical practice.

71 Introduction

72	Pleural infection is a complex, heterogeneous, and challenging clinical entity associated with
73	prolonged hospitalization, significant healthcare costs, and high morbidity and mortality ¹⁻⁴ . Clinical
74	management frustrations arise due to insensitivities in conventional microbiologic diagnostics (culture-
75	positive rates of only 20-60% ⁵⁻⁹), resulting in prolonged and potentially inappropriate broad-spectrum
76	antimicrobial use. Culture-based diagnostic sensitivity is poor due to multiple factors, including empiric
77	antibiotic therapy prior to pleural sampling, low pathogen concentration in pleural fluid, and difficulties
78	in cultivating fastidious microorganisms ^{4,10} . These limitations have obscured characterization of the
79	pleural 'microbiome' (i.e. the entire microbial community), hampering clinical progress ¹¹ .
80	Molecular diagnostics enable culture-independent microbial identification from clinical specimens ¹² .
81	Such techniques include shotgun metagenomics, metataxonomics, and quantitative PCR (qPCR),
82	each having unique capabilities and drawbacks. Shotgun metagenomics involves total microbiome
83	DNA sequencing of a sample, allowing strain-level detection of bacteria, archaea, fungi, parasites,
84	and DNA viruses, along with their putative functions (e.g. antimicrobial resistance, virulence).
85	However, metagenomics overlooks RNA viruses, and cannot readily differentiate living from dead
86	microbes. Metataxonomics involves next-generation amplicon sequencing of conserved bacterial
87	(16S ribosomal RNA [rRNA]) or fungal internal transcriber spacer (ITS) regions to characterize
88	bacterial or fungal consortia, respectively; however, these methods typically only resolve microbiota to
89	the genus level, and cannot be used for relative taxon quantification due to highly variable 16S
90	rRNA/ITS copy numbers amongst species. Finally, qPCR is an inexpensive, same-day diagnostic
91	method, with broad resolution ranging from strain to domain level; however, this method is typically
92	limited to <i>a priori</i> target taxa ^{13,14} .
93	Several recent studies have applied culture-independent techniques to characterize pleural infections.
94	This collective work has revealed a pleural microbiome that is often polymicrobial and characterized
95	by a diverse range of classical pathogens and bystander microbes ^{7,8,15-21} . Earlier investigations
96	implemented bacterial metataxonomics to profile the bacterial microbiome ^{7,8,15,21} ; however, three
97	recent studies have implemented metagenomics to more comprehensively profile pleural
98	microbiota ^{16,19,20} . Xu et al. 2022 found bacterial dominance in 80 adult Chinese patients with pleural
99	infections, most commonly Streptococcus and Prevotella spp., although fungi were occasionally
100	identified ¹⁶ . However, the authors only reported taxonomic findings to the genus level, limiting in-

- 101 depth understanding of microbiome composition and diversity¹⁶. Liu *et al.* 2023 reported on a single
- 102 case study of viral pleurisy caused by Epstein-Barr virus, which was successfully treated with
- 103 acyclovir²⁰. Finally, Liu *et al.* 2023 examined microbiomes of pleural and ascitic fluid in 92 specimens
- 104 retrieved from 32 Chinese children, identifying Klebsiella pneumoniae as the dominant pathogen
- 105 (*n*=17), followed by Escherichia coli (*n*=9), and Acinetobacter baumannii (*n*=7); yeasts (*n*=6) and
- 106 several viruses (n=33) were also identified¹⁹. In all three studies, metagenomics yielded a higher
- 107 pathogen positive rate than conventional culture^{16,19,20}.
- 108 To expand knowledge of the pleural microbiome in other cohorts, we undertook a prospective,
- 109 observational, single-center pilot study of 26 consecutive patients presenting with suspected pleural
- 110 infection at an Australian hospital, and 10 consecutive control patients lacking clinical suspicion of
- 111 pleural infection. Next, we compared the diagnostic performance of microbe-enriched shotgun
- 112 metagenomics, bacterial metataxonomics, panbacterial qPCR, and panfungal qPCR with
- 113 conventional culture.

114 Methods

115 *Ethics Statement*. The study was approved by The Prince Charles Hospital Human Research Ethics

116 Committee (HREC/2022/QPCH/81858) and the Sunshine Coast Hospital and Health Service

117 Research Governance Office. All participants provided written informed consent.

118 Study Participants. All patients ≥18 years of age presenting with suspected pleural infection

119 (denoted with a '-P' suffix) admitted between March and November 2022 to the Sunshine Coast

120 University Hospital (SCUH), QLD, Australia, and undergoing a diagnostic and/or therapeutic

121 procedure for suspected pleural infection, were prospectively invited.

122 Due to the lack of a 'gold-standard' pleural infection confirmation test, 'clinical likelihood of pleural

123 infection' was objectively stratified by a specialist respiratory physician using predefined clinical

124 criteria: 1. Probable Pleural Infection: (i) clinical evidence of pleural infection based on fever, elevated

125 white cell count with left shift, pleurisy presence, raised inflammatory markers, and suitable clinical

126 presentation; AND (ii) either direct evidence of pleural infection defined as the presence of Gram stain

127 and/or culture positivity on pleural fluid; OR indirect evidence of pleural infection based upon pleural

128 fluid pH <7.2 as measured on a blood gas analyser and/or glucose <3.0 mmol/L AND (iii)

accompanied by at least two of the following criteria: serum C-reactive protein (CRP) >100 mg/L;

130 complex pleural fluid and evidence of infection on imaging (pleural fluid loculation/septation on

131 ultrasound and/or computed tomography); fever (>38.0°C). 2. Possible Pleural Infection: (i) clinical

132 evidence of pleural infection (as defined in (i) above), AND (ii) negative Gram stain and culture

133 negative on pleural fluid AND pH ≥7.2 and glucose >3.0 mmol/L) AND (iii) accompanied by at least 2

134 of the following criteria: CRP >100 mg/L; complex (i.e. loculated) pleural fluid collection on imaging;

135 fever (≥38.0 °C). 3. Unlikely pleural infection: (i) No clinical evidence of pleural infection, AND (ii) all of

the following criteria are met: pleural fluid Gram stain and culture negative with pH ≥7.2, glucose >3.0

137 mmol/L, serum CRP <100 mg/L, uncomplicated effusion on CT and or ultrasonographic imaging, and

an alternate diagnosis confirmed (i.e. heart failure, malignancy). Based on these criteria, 26

139 consecutive patients with clinically suspected pleural infections were recruited.

140 For the control group, patients with pleural effusions without clinical suspicion for pleural infection at

141 the time of sampling (denoted with a '-C' suffix), were enrolled. These individuals were approached if

142 they had an alternative effusion cause (e.g., malignancy or heart failure), absence of clinical history to

143 support active infection, and simple effusion appearance on ultrasound and/or computed tomography. 144 Patients were excluded if they had prior sampling of the pleural space, any clinical concern for current 145 or recent infection, concomitant abdominal ascites, hepatic hydrothorax, or antibiotic administration 146 within 3 weeks of pleural sampling. Ten participants meeting these criteria were enrolled as non-147 infected control subjects. 148 Specimen Collection, Storage, and Processing. The study scientific and pathology teams were 149 provided participant categorisation by the study clinicians ('-P' vs. '-C') but no other information. For 150 the pleural infection cohort, specimens were collected as soon as practicable using aseptic technique. 151 Antibiotic commencement ranged from 21 days prior to pleural sampling to immediately post-pleural 152 aspiration (Table S1). Following 10mL 1% lidocaine subcutaneous administration, between 10 and 153 60mL pleural fluid was collected into two sterile specimen pots. One pot was immediately mixed with 7mL stabilization agent²² for total DNA extraction (bacterial metataxonomics and gPCR); the second 154 155 pot contained only pleural fluid for culture and host DNA depletion and extraction (metagenomics). 156 Specimens were immediately stored at 4°C until processed. In parallel, specimens were also 157 collected for routine microscopy (cell count, white blood cell differential, Gram stain), and biochemistry 158 analyses (pleural fluid pH, protein, glucose, lactate dehydrogenase; serum CRP). 159 Microbial culturing was undertaken by both SCUH's onsite Pathology laboratory and our Research 160 laboratory, with VITEK 2 (bioMérieux, NSW, Australia) or Illumina NovaSeg 6000 whole-genome 161 sequencing (WGS; Australian Centre for Ecogenomics, QLD, Australia) used respectively to confirm 162 species identity. Bacterial metataxonomics was carried out using Illumina MiSeq 300bp V3-V4 16S 163 rRNA amplicon paired-end sequencing²³ (Ramaciotti Centre for Genomics, NSW, Australia). 164 Metagenomic sequencing of host-depleted DNA²⁴ was performed using Illumina NovaSeq 6000 165 150bp paired-end reads (17-27 million reads/sample; Azenta Life Sciences, China). For gPCR 166 analyses, total genomic DNA was tested against panbacterial (16S rRNA)²⁵, panfungal (28S rRNA)²⁶, 167 and human $(\beta$ -globin)²⁷ gPCR assays to quantify microbial-to-host load. For the panbacterial gPCR 168 assay, a cycles-to-threshold (C_T) cut-off value of 31 was used to delineate pleural infection-positive 169 versus -negative cases. Further methodological details are described in Supplementary Methods. 170 Statistical Analyses. To determine diagnostic test performance, 'Probable Pleural Infection' was 171 used as the infection-positive reference. Specificity, sensitivity, positive predictive value (PPV), and 172 negative predictive value (NPV) were calculated for microbial culture, qPCR, bacterial

- 173 metataxonomics, and metagenomics. Spearman's rank correlation (r_s) was used to determine pleural
- 174 infection/no-infection diagnostic correlations between the four testing methods.

175 Results

176 Study participants and clinical outcomes. Twenty-six participants (n=7 female; median age=67 177 vears [range 20 - 95]) with suspected pleural infection had an exudative pleural effusion as defined 178 by Light's criteria²⁸. Twenty-four (92%) had loculated (complex) pleural effusions on ultrasound and/or 179 computed tomography imaging, with 20 (77%) also having associated lung consolidation at the time 180 of cross-sectional imaging. Twenty-five (96%) underwent intercostal catheter insertion, whereas one 181 underwent diagnostic/therapeutic needle aspiration. All 26 patients received broad-spectrum 182 antimicrobial therapy (Table S1). Intrapleural enzyme therapy (5mg DNase and 10 mg tissue 183 plasminogen activator) was administered in 17 participants (65%), and four (15%) required surgical 184 decortication (Table 1 & Table S2). Thirty-day mortality was 12% (n=3). 185 Among the 10 control subjects, 9 were diagnosed with malignant pleural effusion (MPE), and one with 186 decompensated congestive heart failure (Table 1 & Table S2). Thirty-day mortality was not recorded 187 for this cohort. 188 Conventional culture performance. Pathology lab testing returned 10 (38%) microbial culture-

positive results from the pleural infection cohort (**Table 2**), whereas only six (23%) were culture-

190 positive from Research lab testing; however, there was 100% overlap with the Pathology results.

191 Unexpectedly, pleural fluid from two control participants, SCHI0152-C and SCHI0175-C, cultured

192 Candida parapsilosis and Moraxella osloensis, respectively, in the Research lab. No microbes were

193 cultured in the control cohort by the Pathology lab.

194 *qPCR performance.* Positive bacterial detection was achieved with panbacterial qPCR in 14/26

195 (54%) suspect pleural infection cases (Table 2). All panbacterial qPCR-positive results were also

196 bacteria-positive according to metagenomics and/or bacterial metataxonomics (Table 2). One of the

197 10 control cases was panbacterial qPCR-positive, albeit at a borderline C_T value of 30.9; this result

198 was not supported by any of the other tested methods. Panfungal qPCR did not identify fungi in any

199 pleural infection or control cohort specimens.

200 Bacterial metataxonomic and shotgun metagenomic performance. Together, bacterial

201 metataxonomics and metagenomics identified 16/26 (62%) suspect pleural infection cases as

202 infection-positive, with 14/26 (54%) cases determined by each individual method. Metagenomics

identified 7/14 (50%) cases as polymicrobial, vs. 5/14 (36%) polymicrobial cases using bacterial

204 metataxonomics (**Table 2 & Figure 1**). Despite both methods identifying 14 pleural infection cases

205 each, only 12 overlapped, and only three of these cases were identified as polymicrobial by both

206 methods (Table 2). Far fewer taxa were identified by bacterial metataxonomics in two of these three

207 cases (SCHI0131-P, SCHI0172-P) (**Table 2**).

208 Molecular diagnostics versus microbial culture performance. Compared with our 'pleural

209 infection-positive' clinical reference classification, all molecular diagnostic methods demonstrated

superior sensitivity and NPVs compared with microbial culture (Table 3). As expected, specificity and

211 PPVs remained high across all diagnostic methods.

212 Conventional culture somewhat correlated with molecular methods (metagenomics: $r_s=0.56$ [p<0.001];

bacterial metataxonomics: $r_s=0.39$ [p=0.05]; panbacterial qPCR: $r_s=0.39$ [p=0.05]) (Figure 3).

214 Metagenomics demonstrated the strongest correlation across methods (bacterial metataxonomics:

215 $r_s=0.69$ [p<0.001]; panbacterial qPCR: $r_s=0.69$ [p<0.001]; conventional culture: $r_s=0.56$ [p<0.01]). The

216 strongest individual correlation was between panbacterial qPCR and bacterial metataxonomics

217 (r_s =0.85; p<0.001; Figure 3); this result was expected as both methods target the 16S rRNA gene.

218 Pleural infection aetiology. A diverse array of oro-naso-hypopharyngeal-, oral-, dental-, respiratory

219 tract-, and gut-associated microbes were detected in the 14 metagenomic infection-positive

220 specimens (Table 2 & Figure 1). Streptococci (n=5; 2 x S. intermedius, 2 x S. pyogenes, 1 x S. mitis)

dominated, followed by Prevotella spp. (n=2; P. oris and P. pleuritidis), Staphylococcus spp. (n=2; S.

222 aureus and S. saprophyticus), and Klebsiella pneumoniae (n=2) (Table 2). Seven (50%) pleural

223 infection cases were monomicrobial according to metagenomics, of which two harboured S.

224 intermedius, along with one each of K. pneumoniae, S. saprophyticus, S. aureus, Enterococcus

faecium, and Escherichia coli (Table 2 & Figure 2). In contrast, bacterial metataxonomics identified

nine (35%) monomicrobial pleural infection cases, of which four were Streptococcus sp., along with

227 one each of Escherichia-Shigella sp., Fusobacterium sp., Haemophilus sp., Klebsiella sp., and

228 *Prevotella* sp. (Table 2 & Figure 2). Five monomicrobial cases overlapped with the two meta-omics

229 methods; however, bacterial metataxonomics erroneously assigned two monomicrobial pleural

230 infection cases, SCHI0132-P and SCHI0143-P, as 'Streptococcus', despite the SCHI0132-P isolate

being confirmed as coagulase-negative *Staphylococcus* sp. by VITEK 2 (**Table 2**), indicating a

232 probable bacterial metataxonomic database error for this genus.

233 As expected, bacterial metataxonomics failed to identify fungi or viruses in the pleural infection cases,

234 whereas conventional culture and metagenomics both identified the yeast, *Pichia kudriavzevii*, in

- 235 SCHI0131-P. Metagenomics further identified the fungi Rhizoctonia solani, Wallemia mellicola,
- 236 Meyerozyma guilliermondii, Truncatella angustata, Cokeromyces recurvatus, Bipolaris maydis,
- 237 Candida orthopsilosis, and Gilbertella persicaria in SCHI0131-P (subject suffered from confirmed
- Boorhaaves syndrome), Candida dubliniensis in SCHI0140-P, and Candida tropicalis, Fonsecaea
- 239 *pedrosoi*, and *Pyricularia pennisetigena* in SCHI0125-P. In all instances, fungi were in relatively low
- abundance. Metagenomics also identified bacteriophages in 5/26 infection-positive cases, with
- 241 Staphylococcus phage Andhra seen in SCHI0123-P, SCHI0125-P, SCHI0127-P, and SCHI0128-P,
- and Streptococcus phage SM1 seen in SCHI0131-P. Staphylococcus phage Andhra was among the
- 243 most dominant taxa seen in SCHI0125-P and SCHI0128-P, indicating very high phage levels in
- 244 pleural fluid; both specimens harboured S. aureus according to metagenomics, and SCHI0125-P also
- had S. saprophyticus according to culture and WGS (Table 2 & Figure 2).
- 246 Metagenomics unexpectedly found microbes in 2/10 control cases (Table 2). The non-pathogenic
- 247 DNA virus, adeno-associated dependoparvovirus A, was identified in SCHI0173-C although no
- 248 helper virus was observed and M. osloensis was confirmed in SCHI0175-C. C. parapsilosis cultured
- from SCHI0152-C was not detected, suggesting possible operator contamination during specimen
- 250 collection or processing. Bacterial metataxonomics failed to identify the culture-confirmed M.
- 251 osloensis in SCHI0175-C, but identified Escherichia-Shigella in SCHI0152-C (1453 reads) and
- 252 Corynebacterium in SCHI0173-C (190 reads), findings that were not supported by the other methods,
- again likely due to contamination.
- 254 *Microbiology and clinical outcomes.* Of the three pleural infection cases with a <30-day mortality,
- two (SCHI0128-P and SCHI0134-P) were infected with K. pneumoniae, and two (SCHI0131-P and
- 256 SCHI0128-P) had polymicrobial infections according to metagenomics. In contrast, no patient
- surviving beyond 30 days (*n*=23) harbored *Klebsiella* spp. according to any testing method.
- 258 Antimicrobial resistance gene detection. In silico antimicrobial resistance gene detection only
- identified innate drug resistance genes, with no evidence of acquired resistance development in any
- 260 case (**Table S1**).

261 Discussion

262 Clinical decision-making in suspected pleural infection is challenging due to low culture positivity rates⁵⁻⁸, resulting in frequent diagnostic uncertainty and antimicrobial overuse. Recent work^{7,8,15,16,19} 263 264 has highlighted potential advantages of molecular methods for diagnosing and determining the 265 aetiology of pleural infection. Our pilot feasibility study adds to this growing body of work, being one of 266 the first studies to apply shotgun metagenomics on pleural infections, and the first to prospectively 267 collect and profile consecutive pleural fluid specimens. Our findings suggest that all three culture-268 independent molecular techniques tested in our study - metagenomics, bacterial metataxonomics, 269 and panbacterial qPCR - have excellent performance characteristics for pleural infection diagnosis, 270 and may be superior to conventional culture for diagnosis and aetiologic confirmation. Panbacterial 271 gPCR stands out as a cost-effective, simple, and same-day diagnostic that could be readily 272 implemented as a routine test for pleural fluid specimens; such a test may assist with both antimicrobial stewardship efforts and rapid treatment decision-making²⁹. In support of its clinical utility, 273 274 panbacterial qPCR showed excellent diagnostic performance (sensitivity 82%, specificity 95%, PPV 275 93%, NPV 86%) and strong correlation with shotgun metagenomics, bacterial metataxonomics, and 276 conventional culture. In line with recent molecular studies^{7,8,15-17}, we confirm that pleural infections can be either 277 278 monomicrobial or polymicrobial, with predominant microbes most likely originating from oral, dental, or 279 upper and lower respiratory tract sources, and occasional incursion from gut-borne pathogens (e.g. E. 280 coli, Enterococcus faecium, K. pneumoniae) (Table 2). Furthermore, metagenomics and bacterial 281 metataxonomics unveiled greater microbial heterogeneity than could be detected by conventional 282 culture. Similar to recent work^{16,19}, we observed that polymicrobial bacterial infection was also 283 occasionally associated with fungal coinfection (albeit in very low abundance) using metagenomics, 284 confirming the challenging nature of diagnosing and treating complex polymicrobial pleural infections 285 across microbial domains. Streptococcal and staphylococcal phages were also seen in five cases of

286 pleural infection, with their host species not always detected, suggesting possible lytic activity towards

- their host within the pleural space, or incidental phage transit from other body sites³⁰. Although not
- examined here, others have shown that phage presence in clinical specimens can negatively impact

289 culture rates³¹. Despite low sample numbers, we found that *K. pneumoniae* presence was associated

290 with greater risk of mortality, consistent with recent bacterial metataxonomic study that showed an

association between Enterobacteriaceae and mortality⁸.

292 Immediate antimicrobial administration upon suspicion of pleural infection is important for preventing 293 sepsis³²; however, this practice may negatively affect pleural infection diagnostic rates. Despite this, 294 many prior pleural microbiome studies have identified 100% infection positivity using molecular 295 testing^{7,8,15}. In contrast, only 62% of suspected pleural infections in our study had detectable microbes 296 according to molecular and/or culture assessment. Our lower positivity rate likely reflects our 297 prospective, consecutive recruitment of participants without prior knowledge of culture results or 298 pleural biochemistry, an approach that captures the diagnostic uncertainty facing clinicians in real-299 world practice. Only two other studies have not used prior knowledge of pleural fluid biochemistry or 300 microbiology for molecular pleural infection identification and characterisation; their infection positivity rate was 70%^{16,17}. Our finding that 38% of suspected pleural infection patients did not have detectable 301 302 microbes according to any method suggests that a subset of patients with clinically suspected pleural 303 infection may instead have sterile pleural effusions at the time of sampling. In support of this 304 conclusion, these patients had more benign pleural biochemistry using recognised cut-off values (i.e. 305 pH <7.2; glucose <3.0 mmol/L)¹ (**Table 1**). A second possibility is that some infections were missed 306 due to prior antibiotic exposure; however, others have shown that molecular approaches are less 307 impacted by prior antibiotics than conventional culture^{7,16}. A third possibility is that human DNA 308 depletion prior to metagenomic sequencing may have limited our ability to detect extracellular 309 microbial DNA²⁴. To overcome this issue, deeper metagenomic sequencing on total DNA can be 310 conducted; however, such an approach is costly, and risks missing low-abundance microbes due to 311 overwhelming human DNA signal^{24,33}. Prospective randomized trials are needed to understand 312 whether a truncated antibiotic course can be safely used in people with likely sterile effusions as 313 identified with molecular diagnostics, and to quantify the impact of prior antibiotic administration on 314 culture or molecular detection sensitivity.

Sensitive molecular assays come with the trade-off that microorganism presence might represent either a contaminant or a bona fide pathogen. To assess this issue, we investigated whether the control group, predominantly comprised of MPEs, had a pleural microbiome. Although most controls had a sterile pleural space, one MPE patient was positive for *Moraxella osloensis* on culture, WGS, and metagenomics. *M. osloensis*, a commensal of human skin and the upper respiratory tract, most

320 commonly causes infection in cancer patients³⁴; it is thus feasible that this patient had an 321 undiagnosed infection alongside their MPE. Three other MPE patients also unexpectedly yielded 322 microbes: C. parapsilosis was cultured from SCHI0152-C, and bacterial metataxonomics identified 323 Corynebacterium and Escherichia-Shigella in SCHI0173-C and SCHI0152-C, respectively; however, 324 these findings were not supported by the other methods. Although specimen or sampling 325 contamination represents the most plausible explanation for these results, a recent bacterial 326 metataxonomic study suggested that non-infective pleural disease may contain unique microbial 327 signatures^{7,35}. Strict aseptic practice during specimen collection and processing can mitigate some of 328 these false-positive cases. However, microbial contamination may still occur at many stages of 329 sample handling and analysis, including procedural contamination (e.g. remnant microbial DNA in the 330 specimen jars or local anaesthetics), or residual DNA from transient microbial seeding of the pleura. 331 In addition, index hopping and 'kitome' contamination are known drawbacks of next-generation 332 sequencing, especially in low-biomass specimens like pleural fluid³³. Careful consideration of these 333 challenges will be important in the design of larger prospective studies. Further studies examining the 334 pleural microbiome across a spectrum of pleural diseases, including in people with MPE and 335 congestive heart failure, will also be illuminating. 336 Other challenges also complicated interpretation of pleural diagnosis and aetiology, including 337 difficulties distinguishing background noise from true microbial signal, lack of appropriate 338 methodology for detecting RNA viruses, and uncertainty regarding microbial causality and 339 pathogenicity (e.g. the role of bystander microbes in pleural disease development and prognosis), 340 particularly in polymicrobial infections. Shotgun metatranscriptomics, which involves total RNA 341 sequencing of microbiome transcripts, may address these difficulties. However, to our knowledge, this 342 technique has not yet been undertaken to investigate pleural infections, so its value in this cohort 343 remains unclear. Perhaps most challenging of all is the current lack of gold-standard clinical 344 diagnostic criteria for pleural infection. In clinical practice, an integrated approach is taken to weigh 345 multiple factors to make a probabilistic diagnosis, including pleural biochemistry, host response, and 346 imaging. In this study, we attempted to standardize integrated probabilistic diagnostic classification by 347 formulating a pragmatic reference standard to compare diagnostic performance between modalities. 348 However, the issue of a validated diagnostic gold-standard remains an unresolved challenge. It is also 349 important to consider the impact of incorporation bias³⁶ when interpreting the performance of

- 350 conventional culture results, given that such results contribute to the diagnostic 'reference standard',
- 351 thereby inflating culture performance estimates.
- 352 In conclusion, this prospective study demonstrates the feasibility of, and challenges associated with,
- 353 molecular tests for pleural infection diagnosis. Whilst such methods hold great clinical utility and
- 354 potential superiority in routine pleural infection diagnostics, questions and challenges remain. A large,
- 355 rigorous study comparing molecular and culture-based diagnostic techniques in pleural infection is
- 356 now required to further address these opportunities for diagnostic advancement, along with the
- 357 associated challenges in eventual clinical translation.

358	Author Contributions: The authors confirm contribution to the paper as follows: study conception
359	and design, PTB, TB, JG, OSS, AB, DSS, EPP; data collection, PTB, TB, JG, OSS, AB, JA, DSS,
360	EPP; analysis and interpretation of results, PTB, TB JG, OSS, AB, SS, TRD, DSS, EPP; draft
361	manuscript, PTB, TB, DSS, EPP; preparation of manuscript, PTB, JG, OSS, AB, SS, TRD, DSS,
362	EPP. All authors reviewed the results and approved the final version of the manuscript.
363	
364	Funding: This work was funded by Wishlist Sunshine Coast Hospital Foundation (award 2021-04-
365	CRG to TB, OO, JG, DSS, and EPP) and Advance Queensland (awards AQIRF0362018 to EPP and
366	AQIRF095-2020-CV to OSO). PTB has no funding to declare.
367	
368	Conflicts of Interest Statement: The authors declare no conflict of interest. The funders had no role
369	in study design, in the collection, analyses, or interpretation of data, in manuscript writing, or in the
370	decision to publish the results.
371	
372	Acknowledgements: We thank Emma Seaniger and Louise McIntosh for assistance with sample
373	collection and study coordination, Michael Caffery and the Pathology Queensland laboratory
374	scientists for their assistance with culture, and the Australian BioCommons team (led by Ashley
375	Dungan at University of Melbourne, and Melissa Burke at University of Queensland) for providing
376	QIIME 2 training.

377 Figure Legends

378

379	Figure 1. Metagenomic	profiles identified from 26 s	uspected	pleural infection s	pecimens and

- 380 10 control cohort specimens. *Conventional culture positive; ^16S ribosomal RNA (panbacterial)
- 381 quantitative PCR positive; #Whole-genome sequencing-confirmed (from culture). Dominant taxa are
- 382 labelled on each bar.
- 383

384 Figure 2. Bacterial 16S ribosomal RNA (rRNA) metataxonomic profiles identified from 26

- 385 suspected pleural infection specimens and 10 control cohort specimens. *Conventional culture
- 386 positive; ^16S ribosomal RNA (panbacterial) quantitative PCR positive; #Whole-genome sequencing
- 387 result from culture; ‡Likely incorrect assignment of Staphylococcus as Streptococcus (1 case
- 388 confirmed as a coagulase-negative Staphylococcus by MALDI-TOF analysis of culture). Dominant
- 389 taxa are labelled on each bar.
- 390
- Figure 3. Correlation matrix of the pleural infection diagnostic methods used in this study.
- 392 1=perfect correlation; -1=no correlation. Conventional culture showed the weakest correlation when
- 393 compared with each of the three molecular methods.

Table 1. Clinical, Demographic and Outcome Data

	Suspected	Non-infectious Pleural
	Pleural Infection	Effusion (Control)
Clinical / Demographics		
Number of participants in group, <i>n</i>	26	10
Age in years (median, range)	67 (20-95)	78 (41-87)
Female sex, n (%)	7 (27)	2 (20)
Immunosuppression, n (%)	3 (12)	1 (10)
Fever, <i>n</i> (%)	23 (90)	-
ICU admission, n(%)	6 (23)	-
Biochemical		
Serum White Cell count, cells $x10^{9}$ /L (median, range)	14.5 (8.4-33.6)	8.3 (4.3-15.2)
Serum C-reactive protein, mg/L (median, range)	193 (39-547)	56 (5-124)
Serum Procalcitonin, μ g/L (median, range)	0.6 (0.1-9.6)	0.2 (0.1-0.3)
Serum LDH, unit/L (median, range)	236 (108-477)	208 (160-391)
Serum Protein, g/L (median, range)	61 (49-76)	62 (45-72)
Fluid LDH, unit/L (median, range)	865 (173-17400)	239 (81-672)
Fluid Protein, g/L (median, range)	46 (23-58)	43 (37-46)
Fluid pH (median, range)	7.0 (6.6-7.5)	7.4 (7.3-7.5)
Fluid glucose, mmol/L (median, range)	3.9 (2.4-11.9)	6.3 (4.6-10.0)
Imaging		
Consolidation, n (%)	20 (80)	_
Complex appearance of effusion, n (%)	24 (92%)	-
Outcome Data		
IPE, <i>n</i> (%)	17 (65)	_
CTS, <i>n</i> (%)	4 (15)	_
30-day mortality, <i>n</i> (%)	3 (12)	_
Pleural infection Likelihood* (%)	1=0%, 2=38.5%,	1=100%, 2=0%, 3= 0%
	3=61.5%	

395

396 Abbreviations: Cardiothoracic Surgical decortication; IPE, Intrapleural Enzyme therapy; LDH, Lactate

dehydrogenase. * 1 = Unlikely pleural infection, 2 = Possible pleural infection: 3 = Probable pleural

398 infection.

Table 2. Pleural space diagnostic performance across 26 pleural infection diagnosed participants and 10 controls with a diagnosed non-pleural

infection aetiology

Participant ID	Metagenomic result [#]	Bacterial metataxonomic result [†]	Culture result, Research Lab (WGS result)	Culture result, Pathology Lab (MALDI-TOF result)	Panbacterial qPCR [‡]
Diagnosed w	ith Pleural Infection				
SCHI0123-P	Polymicrobial (Fusobacterium nucleatum, Fusobacterium hwasookii, Staphylococcus phage Andhra, Prevotella loescheii, Rothia mucilaginosa, Enterococcus faecium, Fusobacterium sp. oral taxon 203)	Monomicrobial (<i>Fusobacterium</i>)	NG	NG	Yes (<i>C</i> ₇ =20.8)
SCHI0125-P	Polymicrobial (Staphylococcus phage Andhra, Prevotella oris, Enterococcus faecium, Streptococcus mitis, Streptococcus anginosus, Escherichia coli ^a , Streptococcus pneumoniae, Fonsecaea pedrosoi, Candida tropicalis, Pyricularia pennisetigena, Staphylococcus aureus ^b)	Monomicrobial (<i>Prevotella</i>)	Escherichia coli*, Staphylococcus saprophyticus*	Escherichia coli	Yes (<i>C</i> ₇ =25.7)
SCHI0126-P	ND	ND	NG	NG	No (C7=33.9)
SCHI0127-P	Polymicrobial (<i>Streptococcus pyogenes</i> , <i>Staphylococcus</i> phage Andhra, <i>Streptococcus dysgalactiae</i> , <i>Streptococcus agalactiae</i> , <i>Enterococcus faecium</i> , <i>Rothia mucilaginosa</i>)	Monomicrobial (Streptococcus)	Positive (not characterised)	Streptococcus pyogenes	Yes (<i>C</i> ₇ =27.5)
SCHI0128-P	Polymicrobial (Klebsiella pneumoniae, Staphylococcus phage Andhra, Mycoplasma hyorhinis, Carnobacterium divergens, Actinomyces odontolyticus, Rothia mucilaginosa, Streptococcus mitis, Haemophilus parainfluenzae, Enterococcus faecium, Streptococcus parasanguinis, Staphylococcus aureus)	ND	NG	NG	No (C ₇ =35.3)

	Polymicrobial (Streptococcus mitis, Streptococcus anginosus, Streptococcus	Polymicrobial	1		1
		rorymerobia			
	pneumoniae, Streptococcus sp. oral taxon 431, Streptococcus oralis,	(Streptococcus,			
	Streptococcus salivarius, Gemella haemolysans, Streptococcus	Streptococcus			
	pseudopneumoniae, Streptococcus sp. ChDC B345, Streptococcus gordonii,	opneumoniae, Streptococcus sp. ChDC B345, Streptococcus gordonii, anginosus,			
	Streptococcus parasanguinis, Streptococcus cristatus, Streptococcus sp. HSISM1,	Granulicatella,			
	Streptococcus australis, Streptococcus sp. oral taxon 064, Streptococcus sp.	Streptococcus salivarius,			
	FDAARGOS_192, Streptococcus intermedius, Streptococcus sp. A12, Veillonella	Gemella, Prevotella			
	atypica, Actinomyces odontolyticus, Streptococcus sanguinis, Gemella sanguinis,	jejuni, Veillonella,			
	Streptococcus thermophilus, Capnocytophaga leadbetteri, Streptococcus equinus,	Streptococcus			Yes (C =17.7)
	Streptococcus viridans, Rothia dentocariosa, Capnocytophaga gingivalis,	constellatus, Prevotella			
	Veillonella parvula, Rothia mucilaginosa, Streptococcus vestibularis,	melaninogenica;	Pichia kudriavzevii*	Piahia kudriauzvair	
SCHI0131-	Streptococcus sp. HSISS2, Prevotella jejuni, Streptococcus constellatus,	Neisseria perflava,			
P ^e	Streptococcus sp. I-P16, Streptococcus sp. I-G2, Veillonella dispar,	Neisseria,			$\text{res}(C_7 = 17.7)$
	Bifidobacterium longum, Streptococcus sp. HSISS3, Gemella morbillorum,	Fusobacterium		anaerobic bacteria	
	Haemophilus influenzae, Streptococcus sp. HSISS1, Atopobium parvulum,	periodonticum,			
	Streptococcus dysgalactiae, Streptococcus pyogenes, Streptococcus agalactiae,	Prevotella salivae,			
	Staphylococcus aureus, Prevotella salivae, Prevotella melaninogenica, Tannerella	Haemophilus influenzae,			
	sp. oral taxon HOT-286, Actinomyces sp. oral taxon 171, Actinomyces oris,	Leptotrichia,			
	Capnocytophaga sputigena, Haemophilus parainfluenzae, Neisseria subflava,	Capnocytophaga			
	Campylobacter showae, Streptococcus phage SM1, Streptococcus mutans,	gingivalis,			
	Streptococcus sobrinus, Streptococcus acidominimus, Lactococcus lactis,	Capnocytophaga			
	Lachnospiraceae bacterium oral taxon 500, Actinomyces naeslundii, Actinomyces	leadbetteri, Schaalia			
	viscosus, Capnocytophaga sp. oral taxon 878, Neisseria elongata, Lautropia	odontolytica, Neisseria			
	mirabilis, Fusobacterium periodonticum, Fusobacterium nucleatum, Streptococcus	elongata, Atopobium,			

	<i>ratti</i> , >70 additional taxa ^c)	Fusobacterium,			
		Porphyromonas,			
		Bergeyella, Leptotrichia			
		hongkongensis,			
		Oribacterium, Lautropia,			
		Oribacterium,			
		Selenomonas artemidis,			
		Stomatobaculum,			
		Haemophilus, Prevotella			
		shahii, Rothia)			
SCHI0132-P	Monomicrobial (Staphylococcus aureus ^b)	Monomicrobial	Positive (not	Coagulase-negative	No (<i>C</i> ₇ =33.5)
		(Streptococcus ^d)	characterised)	Staphylococcus sp.	
SCHI0133-P	ND	ND	NG	NG	No (<i>C₇</i> =33.9)
SCHI0134-P	Monomicrobial (Klebsiella pneumoniae)	Monomicrobial	NG	Klebsiella preumoniae	Yes (C-=23.5)
0011101041		(Klebsiella)			100 (07-20.0)
SCHI0135-P	ND	ND	NG	NG	No (<i>C</i> ₇ =34.5)
SCHI0136-P	Monomicrohial (Streptococcus intermedius)	ND	NG	Streptococcus	Yes (C27 5)
501110150-F			NG	intermedius	163 (0/-21.3)
	Polymicrobial (Strantococcus pyocapas, Strantococcus dusgalactica, Candida	Polymicrobial		Streptococcus	
SCHI0140-P	duhliniansis)	(Streptococcus,	NG	pyogenes,	Yes (C7=25.2)
		Streptococcus		Staphylococcus aureus	
		1			1

		pyogenes)			
SCHI0141-P	ND	ND	NG	NG	No (<i>C</i> ₇ =33.5)
SCHI0143-P	Monomicrobial (Staphylococcus saprophyticus)	Monomicrobial (<i>Streptococcus</i> ^d)	NG	NG	Yes (<i>C</i> ₇ =30.1)
SCHI0148-P	ND	ND	NG	NG	No (<i>C</i> ₇ =34.6)
SCHI0149-P	ND	ND	NG	NG	No (<i>C</i> ₇ =31.3)
SCHI0150-P	ND	Monomicrobial (<i>Haemophilus</i>)	NG	NG	Yes (<i>C₇</i> =28.1)
SCHI0157-P	Monomicrobial (Streptococcus intermedius)	Monomicrobial (Streptococcus)	NG	Streptococcus intermedius	Yes (<i>C</i> ₇ =24.2)
SCHI0158-P	ND	Polymicrobial (Fusobacterium, Parvimonas, Eubacterium)	NG	NG	Yes (<i>C</i> ₇ =29.2)
SCHI0159-P	ND	ND	NG	NG	No (<i>C</i> ₇ =32.6)
SCHI0160-P	ND	ND	NG	NG	No (<i>C</i> ₇ =32.3)
SCHI0162-P	ND	ND	NG	NG	No (<i>C</i> ₇ =31.2)
SCHI0163-P	Monomicrobial (Haemophilus parainfluenzae)	Polymicrobial (Haemophilus, Novosphingobium)	NG	NG	Yes (<i>C</i> ₇ =23.5)
SCHI0166-P	Monomicrobial (<i>Escherichia coli</i>)	Monomicrobial (Escherichia-Shigella)	Positive (not characterised)	Escherichia coli	Yes (<i>C</i> ₇ =21.5)
SCHI0169-P	ND	ND	NG	NG	No (<i>C</i> ₇ =33.2)

SCHI0172-P	Polymicrobial (Prevotella pleuritidis, Fusobacterium nucleatum, Prevotella enoeca, Prevotella intermedia, Hallela seregens, Porphyromonas gingivalis, Tannerella forsythia, Prevotella buccae, Prevotella oris, Fusobacterium sp. oral taxon 203, Prevotella nigrescens, Prevotella denticola, Streptococcus pyogenes, Prevotella veroralis, Fusobacterium hwasookii, Prevotella aurantiaca, Bacteroides fragilis, Bacteroides heparinolyticus, Prevotella salivae, Prevotella fusca, Prevotella pallens, Prevotella nanceiensis, Prevotella jejuni, Prevotella oulorum, Prevotella maculosa, Prevotella bivia, Prevotella melaninogenica, Prevotella micans,	Polymicrobial (<i>Enterococcus</i> , <i>Prevotella pleuritidis</i>)	Positive (not characterised)	Fusobacterium nucleatum	Yes (<i>C</i> 7=20.3)
Diagnosed wi	Prevotella amnii, Prevotella conceptionensis, Enterococcus faecium)				
SCHI0151-C	ND	ND	NG	NG	No (<i>C</i> ₇ =32.7)
SCHI0152-C	ND	Monomicrobial (Escherichia-Shigella)	Candida parapsilosis*	NG	No (<i>C</i> ₇ =35.7)
SCHI0161-C	ND	ND	NG	NG	No (C7=36.7)
SCHI0164-C	ND	ND	NG	NG	No (C ₇ =35.9)
SCHI0165-C	ND	ND	NG	NG	No (<i>C</i> ₇ =32.3)
SCHI0168-C	ND	ND	NG	NG	No (<i>C</i> ₇ =32.7)
SCHI0170-C	ND	ND	NG	NG	No (<i>C</i> ₇ =38.7)
SCHI0173-C	Monomicrobial (Adeno-associated dependoparvovirus A)	Monomicrobial (Corynebacterium)	NG	NG	No (<i>C</i> ₇ =31.3)
SCHI0174-C	ND	ND	NG	NG	Yes (<i>C</i> ₇ =30.9)
SCHI0175-C	Monomicrobial (<i>Moraxella osloensis</i>)	ND	Moraxella osloensis*	NG	No (<i>C</i> ₇ =31.9)

Abbreviations: C_{T} , cycles-to-threshold; MALDI-TOF, matrix-assisted laser desorption/ionisation time-of-flight mass spectrometry; ND, not determined; NG, no growth; PE, pleural effusion. Salmon-coloured cells denote possible false-negative results in the Pleural infection cohort. Bolded text denotes footnoted item; gray-shaded fields indicate discordant negative pleural infection diagnosis. [#]Minimum read threshold of ≥400 reads. [†]Minimum read threshold of ≥400 reads. [†]Based on TRIzol interphase DNA extraction. *Cultures subjected to whole-genome sequencing. ^a*Escherichia coli* excluded from the metagenomic output due to its read count being lower than the background (contaminant) signal. ^bNo *S. saprophyticus* or other coagulase-negative staphylococci were identified, suggesting potential taxonomic misassignment or a detection limit issue. ^c*Pichia kudriavzevii* identified in the metagenome data (1963 reads). ^dProbable taxonomic misassignment of certain '*Staphylococcus*' as '*Streptococcus*' using bacterial metataxonomics. ^eSCHI0131-P, yielded exceptionally high and diverse microbial burden across all testing methods; this case differed clinically from others in that the participant had suffered a ruptured oesophagus (Boerhaave syndrome).

 Table 3. Comparative diagnostic accuracy of conventional culture and molecular methods for detecting pleural infection when compared to a surrogate gold-standard pleural infection classification of 'probable pleural infection'*.

	CONVENTIONAL	PANBACTERIAL QPCR	BACTERIAL METATAXONOMICS	METAGENOMICS	COMBINED MOLECULAR
SENSITIVITY (95% CI)	70.6 (44.0-89.7)	82.4 (56.6-96.2)	88.2 (63.6-98.5)	82.4 (56.6-96.2)	100 (80.5-100)
SPECIFICITY (95% CI)	100 (82.3-100)	94.7 (74.0-99.9)	94.7 (74.0-99.9)	89.5 (66.9-98.7)	84.2 (60.4-96.6)
PPV (95% Cl)	100 (73.5-100)	93.3 (68.1-99.8)	93.8 (69.8-99.8)	87.5 (61.7-98.4)	85 (62.1-96.8)
NPV (95% Cl)	79.2 (57.8-92.9)	85.7 (63.7-97.0)	90 (68.3-98.8)	85 (62.1-96.8)	100 (79.4-100)

Abbreviations: CI, confidence interval; NPV, negative predictive value; PPV, positive predictive value; qPCR, quantitative PCR; Combined Molecular, all molecular methods (qPCR, bacterial metataxonomics, metagenomics). **Probable Pleural Infection:* Gram stain and/or culture positive on pleural fluid; or pleural fluid pH < 7.2 and 2 or more of the following: serum C-reactive protein > 100 mg/L; complex pleural fluid on imaging; fever (> 38°C)

References

1. Bedawi EO, Guinde J, Rahman NM, Astoul P. Advances in pleural infection and malignancy. European Respiratory Review 2021;30:200002.

2. Cargill TN, Hassan M, Corcoran JP, et al. A systematic review of comorbidities and outcomes of adult patients with pleural infection. European Respiratory Journal 2019;54:1900541.

3. Brims F, Popowicz N, Rosenstengel A, et al. Bacteriology and clinical outcomes of patients with culture-positive pleural infection in Western Australia: A 6-year analysis. Respirology 2019;24:171-8.

4. Bedawi EO, Ricciardi S, Hassan M, et al. ERS/ESTS statement on the management of pleural infection in adults. European Respiratory Journal 2022:2201062.

5. Maskell NA, Batt S, Hedley EL, Davies CW, Gillespie SH, Davies RJ. The bacteriology of pleural infection by genetic and standard methods and its mortality significance. Am J Respir Crit Care Med 2006;174:817-23.

6. Rahman NM, Maskell NA, West A, et al. Intrapleural use of tissue plasminogen activator and DNase in pleural infection. New England Journal of Medicine 2011;365:518-26.

7. Shiraishi Y, Kryukov K, Tomomatsu K, et al. Diagnosis of pleural empyema/parapneumonic effusion by next-generation sequencing. Infect Dis (Lond) 2021;53:450-9.

8. Kánellakis NI, Wrightson JM, Gerry S, et al. The bacteriology of pleural infection (TORPIDS): an exploratory metagenomics analysis through next generation sequencing. The Lancet Microbe 2022;3:e294-e302.

9. Menzies SM, Rahman NM, Wrightson JM, et al. Blood culture bottle culture of pleural fluid in pleural infection. Thorax 2011;66:658-62.

10. Boyanova L, Vladimir D, Gergova G, et al. Anaerobic microbiology in 198 cases of pleural empyema: a Bulgarian study. Anaerobe 2004;10:261-7.

11. Corcoran JP, Wrightson JM, Belcher E, DeCamp MM, Feller-Kopman D, Rahman NM. Pleural infection: past, present, and future directions. Lancet Respir Med 2015;3:563-77.

12. Schlaberg R, Chiu CY, Miller S, Procop GW, Weinstock G. Validation of Metagenomic Next-Generation Sequencing Tests for Universal Pathogen Detection. Arch Pathol Lab Med 2017;141:776-86.

13. Marchesi JR, Ravel J. The vocabulary of microbiome research: a proposal. Microbiome 2015;3:31.

14. Hilton SK, Castro-Nallar E, Pérez-Losada M, et al. Metataxonomic and metagenomic approaches vs. culture-based techniques for clinical pathology. Front Microbiol 2016;7:484.

15. Dyrhovden R, Nygaard RM, Patel R, Ulvestad E, Kommedal Ø. The bacterial aetiology of pleural empyema. A descriptive and comparative metagenomic study. Clin Microbiol Infect 2019;25:981-6.

16. Xu H, Hu X, Wang W, et al. Clinical application and evaluation of metagenomic nextgeneration sequencing in pulmonary infection with pleural effusion. Infect Drug Resist 2022;15:2813-24.

17. Gimenez-Miranda L, Samhouri BF, Wolf MJ, et al. Diagnostic Yield of 16S Ribosomal Ribonucleic Acid Gene-Based Targeted Metagenomic Sequencing for Evaluation of Pleural Space Infection: A Prospective Study. Mayo Clin Proc Innov Qual Outcomes 2023;7:373-81.

18. Elsheikh A, Bhatnagar M, Rahman NM. Diagnosis and management of pleural infection. Breathe (Sheff) 2023;19:230146.

19. Liu G, Wang L, Li X, et al. The value of next-generation metagenomic sequencing in pathogen detection of pleural effusions and ascites from children with sepsis. Front Cell Infect Microbiol 2023;13:1130483.

20. Liu XP, Mao CX, Wang GS, Zhang MZ. Metagenomic next-generation sequencing for pleural effusions induced by viral pleurisy: A case report. World J Clin Cases 2023;11:844-51.

 Psallidas I, Kanellakis NI, Bhatnagar R, et al. A pilot feasibility study in establishing the role of ultrasound-guided pleural biopsies in pleural infection (The AUDIO Study). Chest 2018;154:766-72.
 Madden DE, Olagoke O, Baird T, et al. Express yourself: quantitative real-time PCR assays for rapid chromosomal antimicrobial resistance detection in *Pseudomonas aeruginosa*. Antimicrob Agents Chemother 2022;66:e0020422.

23. Herlemann DP, Labrenz M, Jurgens K, Bertilsson S, Waniek JJ, Andersson AF. Transitions in bacterial communities along the 2000 km salinity gradient of the Baltic Sea. ISME J 2011;5:1571-9.

24. Nelson MT, Pope CE, Marsh RL, et al. Human and extracellular DNA depletion for metagenomic analysis of complex clinical infection samples yields optimized viable microbiome profiles. Cell Rep 2019;26:2227-40.e5.

25. Nadkarni MA, Martin FE, Jacques NA, Hunter N. Determination of bacterial load by real-time PCR using a broad-range (universal) probe and primers set. Microbiology (Reading) 2002;148:257-66.

26. Ahmadi B, Hashemi SJ, Zaini F, et al. A case of onychomycosis caused by *Aspergillus candidus*. Med Mycol Case Rep 2012;1:45-8.

27. Klaassen CH, Jeunink MA, Prinsen CF, et al. Quantification of human DNA in feces as a diagnostic test for the presence of colorectal cancer. Clin Chem 2003;49:1185-7.

28. Light RW, Macgregor MI, Luchsinger PC, Ball WC, Jr. Pleural effusions: the diagnostic separation of transudates and exudates. Ann Intern Med 1972;77:507-13.

29. Insa R, Marin M, Martin A, et al. Systematic use of universal 16S rRNA gene polymerase chain reaction (PCR) and sequencing for processing pleural effusions improves conventional culture techniques. Medicine (Baltimore) 2012;91:103-10.

30. Nguyen S, Baker K, Padman BS, et al. Bacteriophage transcytosis provides a mechanism to cross epithelial cell layers. mBio 2017;8.

31. Brown-Jaque M, Muniesa M, Navarro F. Bacteriophages in clinical samples can interfere with microbiological diagnostic tools. Sci Rep 2016;6:33000.

32. Lim T. Recent advances in the management of pleural sepsis: What is the evidence? Respirology 1999;4:207-12.

33. Salter SJ, Cox MJ, Turek EM, et al. Reagent and laboratory contamination can critically impact sequence-based microbiome analyses. BMC Biol 2014;12:87.

34. Hadano Y, Ito K, Suzuki J, Kawamura I, Kurai H, Ohkusu K. *Moraxella osloensis*: an unusual cause of central venous catheter infection in a cancer patient. Int J Gen Med 2012;5:875-7.

35. Kwok B, Wu BG, Kocak IF, et al. Pleural fluid microbiota as a biomarker for malignancy and prognosis. Sci Rep 2023;13:2229.

36. Kea B, Hall MK, Wang R. Recognising bias in studies of diagnostic tests part 2: interpreting and verifying the index test. Emerg Med J 2019;36:501-5.

	Metagenomics	Metataxonomics	Panbacterial qPCR	Culture		
Metagenomics	1	0.69	0.69	0.56	1	Spe
Metataxonomics		1	0.85	0.39	0.8 0.6	arman's
Panbacterial qPCR			1	0.39	0.4	rho (<i>r</i> s
Culture				1	0.2	Ű

	Metagenomics	Metataxonomics	Panbacterial qPCR	Culture	≥1 molecular method [†]	PSI Gold Standard*
Metagenomics	1	0.69	0.69	0.56	0.8	0.72
Metataxonomics		1	0.85	0.39	0.8	0.83
Panbacterial qPCR			1	0.39	0.76	0.78
Culture				1	0.63	0.75
≥1 molecular method [†]					1	0.85
PSI Gold Standard*						1

Spearman's rho (r_s)

1

0.8 0.6 0.4 0.2

	PSI cohort																	C	Col	ntr	ol		ho	rt											
100% 90% 80% 70% 60% 50% 40% 30% 20%	Fusobacterium nucleatum Staph phage P. oris		Streptoococcus pyogenes	S. phage Kpn	S. mitis	Staphylococcus aureus		Kpin		Streptococcus intermedius	Streptoococcus pyogenes		Staphylococcus saprophyticus				Streptococcus intermedius					Haemophilus parainfluenzae	E. coli		Prevotella pleuritidus	Γ							Adeno-dependovirus A		Moraxella osloensis
0%	^SCHI0123-P	SCHI0126-P	^*SCHI0127-P	SCHI0128-P	^*SCHI0131-P	*SCHI0132-P	SCHI0133-P	^*SCHI0134-P	SCHI0135-P	^*SCHI0136-P	^*SCHI0140-P	SCHI0141-P	^SCHI0143-P	SCHI0148-P	SCHI0149-P	^SCHI0150-P	^*SCHI0157-P	^SCHI0158-P	SCHI0159-P	SCHI0160-P	SCHI0162-P	^SCHI0163-P	^*SCHI0166-P	SCHI0169-P	^*SCHI0172-P	SCHI0151-C	*SCHI0152-C	SCHI0161-C	SCHI0164-C	SCHI0165-C	SCHI0168-C	SCHI0170-C	SCHI0173-C	^SCHI0174-C	#*SCHI0175-C
 y y o y o y o y o o y o o y Fusobacterium nucleatum Streptococcus mitis Enterococcus faecium Klebsiella pneumoniae Streptococcus sp. oral taxon 431 Prevotella enoeca Rothia mucilaginosa Prevotella intermedia Streptococcus intermedius Candida dubliniensis Haemophilus parainfluenzae Streptococcus sp. oral taxon 064 Streptococcus sp. A12 Veillonella atypica Streptococcus agalactiae Capnocytophaga leadbetteri Streptococcus ridentia 							 Staphylococcus phage Andhra Streptococcus anginosus Streptococcus aureus Streptococcus aureus Streptococcus salivarius Streptococcus selivarius Streptococcus gordonii Actinomyces odontolyticus Fusobacterium hwasookii Streptococcus sp. HSISM1 [Hallella] seregens Prevotella loescheii Fusobacterium sp. oral taxon 203 Escherichia coli Gemella sanguinis Streptococcus thermophilus 								Pree Stree Pree Myo Staa Stree Stre	votel eptoc votel phylccopla phylccopla eptoc eptoc eptoc eptoc phymeno-a eptoc nnere eptoc eptoc	la ol occi la pi sma occci occ	ris leur a hy cus semo us s nas ciat us s ciat s corsy us e corsy us e	oneu itidi orhi solysa p	umo s inis prop ans ChD san rerg atus ralis DA egiva depe a uin a nus	oniae ohyt ogui ens s ARC alis endo	ə icus 34t nis GO	5 5 S_1 rvo	92 viru	s A										

